PPR-151 - Hydroxyurea therapy in Sickle Cell disease patients: Availability, adherence and treatment outcomes

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: PPR-151
• By: MENSAH, Josephine (Pharmacy Directorate, University Of Ghana Medical Centre, Ghana)
• Co-author(s): Dr Josephine Mensah (Pharmacy Directorate, University Of Ghana Medical Centre, Legon, Accra, Ghana / Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana)
  Prof Afia Frimpomaa Asare Marfo (Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana)
  Prof Mercy Naa Aduele Opare-Addo (Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana)
  Mr Amos Amoako-Adusei (Kumasi Centre for Collaborative Research in Tropical Medicine, , Kumasi, Ghana)
  Mr Bright Ansah Adjei (Pharmacy Directorate, University Of Ghana Medical Centre, Legon, Accra, Ghana)
  Mr Karl Osei Afoduo (Pharmacy Directorate, University Of Ghana Medical Centre, Legon, Accra, Ghana)
  Dr Paul Obeng (Department of Pharmacy, Komfo Anokye Teaching Hospital, Kumasi, Ghana)
  Prof Kwame Ohene Buabeng (Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana)
  
• Abstract:

  Introduction:
  Sickle Cell Disease is a significant global health issue, predominantly affecting individuals of African descent. It is the most common inherited blood disorder in children, with potential to impact critical organs. Hydroxyurea is a key medication in Sickle Cell Disease management, with high adherence improving patient outcomes and..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login